These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9012546)

  • 1. Inhibitory effect of metastasis by combined administration with interleukin-2 and sizofiran, a single glucan--immunohistochemical study.
    Kano Y; Kakuta H; Hashimoto J
    Biotherapy; 1996; 9(4):263-9. PubMed ID: 9012546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy of malignant lymphoma with interleukin-2 and sizofiran--a basic study on EL-4 lymphoma-transplanted mice].
    Hashimoto J
    Nihon Jibiinkoka Gakkai Kaiho; 1994 Jul; 97(7):1235-49. PubMed ID: 8064508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of antitumor effect by combined administration with interleukin-2 and sizofiran, a single glucan, on murine EL-4 lymphoma.
    Kano Y; Kakuta H; Hashimoto J
    Biotherapy; 1996; 9(4):241-7. PubMed ID: 9012543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran.
    Kano Y; Kakuta H; Hashimoto J
    Biotherapy; 1998; 11(1):1-6. PubMed ID: 9617459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of anti-tumor effect of interleukin 2 with sizofiran in mice.
    Ikeuchi K
    Keio J Med; 1991 Sep; 40(3):132-8. PubMed ID: 1753556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S; Naruo K; Ootsu K; Houkan T; Shiho O; Tsukamoto K
    Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GM1 antibody or anticancer agents.
    Saijo N; Ozaki A; Beppu Y; Takahashi K; Fujita J; Sasaki Y; Nomori H; Kimata M; Shimizu E; Hoshi A
    J Cancer Res Clin Oncol; 1984; 107(3):157-63. PubMed ID: 6736102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.
    Ciolli V; Gabriele L; Sestili P; Varano F; Proietti E; Gresser I; Testa U; Montesoro E; Bulgarini D; Mariani G
    J Exp Med; 1991 Feb; 173(2):313-22. PubMed ID: 1671080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
    Gately MK; Anderson TD; Hayes TJ
    J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
    Iigo M; Nishikata K; Nakajima Y; Moriyama M
    Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
    Anderson TD; Hayes TJ; Gately MK; Bontempo JM; Stern LL; Truitt GA
    Lab Invest; 1988 Nov; 59(5):598-612. PubMed ID: 3263543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of intraperitoneal administration of recombinant interleukin-2 and streptococcal preparation OK-432 in murine tumors.
    Fujioka T; Ishikura K; Tanji S; Okamoto T; Koike H; Aoki H; Ohhori T; Kubo T
    Int J Immunopharmacol; 1990; 12(4):419-26. PubMed ID: 2391188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of local immunochemotherapy of head and neck cancer].
    Saito T
    Nihon Jibiinkoka Gakkai Kaiho; 1991 Dec; 94(12):1898-912. PubMed ID: 1779275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
    Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
    J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells.
    Selvan RS; Nagarkatti PS; Nagarkatti M
    Int J Cancer; 1990 Jun; 45(6):1096-104. PubMed ID: 1972141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine-related immunomodulating activities of an anti-tumor glucan, sizofiran (SPG).
    Tsuchiya Y; Igarashi M; Inoue M; Kumagai K
    J Pharmacobiodyn; 1989 Oct; 12(10):616-25. PubMed ID: 2534316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.